1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

COVID-19 is primarily a respiratory disease but up to two thirds of hospitalised patients show
evidence of central nervous system (CNS) damage, predominantly ischaemic, in some …

PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …

Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐
standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for …

Two randomized trials in cancer patients evaluating DOACs have been reported [6, 7].
HOKUSAI Cancer was an open-label, non-inferiority trial that randomized 1050 patients with …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …

Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity
and mortality. VTE prevention and treatment are more complex in patients with cancer. The …

The Caprini risk assessment model (RAM) has been validated in over 250 000 patients in
more than 100 clinical trials worldwide. Ultimately, appropriate treatment options are …